A group of 14 educational institutions in Texas and biotech company TissueGen have sued a subsidiary of Johnson & Johnson for infringing two patents covering biodegradable fibres.
The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
NPS Pharmaceuticals suffered a knock-back yesterday, when the US Court of Appeals for the Federal Circuit affirmed a decision which found that claims covering a patent owned by NPS were unpatentable.
Bayer has entered into a global collaboration with biopharmaceutical company Loxo Oncology, in a deal that could be worth more than $1 billion.
Janssen, a subsidiary of Johnson & Johnson, has dropped a lawsuit against Samsung's biopharmaceutical arm Samsung Bioepis.
Excision BioTherapeutics has become the first company to secure exclusive licences from the University of California, Berkeley for “newly discovered” CRISPR gene editors.
Swiss-type second medical use patents can be infringed if a generic producer could have reasonably foreseen that its product would be used intentionally for the claimed use, according to the Supreme Court of the Netherlands.
The US Court of Appeals for the Federal Circuit has reversed its findings in Life Technologies v Promega, nine months after the US Supreme Court limited overseas patent infringement.
The National System for the Management of Genetic Heritage (SisGen) has been officially launched in Brazil.
On November 7, the House Judiciary Committee’s subcommittee on IP took part in the “Sovereign Immunity and the Intellectual Property System” hearing.